IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

(NASDAQ:ICCM) IceCure Medical Ltd. announced that the China National Intellectual Property Administration (CNIPA) has granted the company a new patent in China covering a connector used in its cryogenic technology platform. This patent grant further expands IceCure's global intellectual property portfolio and strengthens the protection of its proprietary cryogenic technologies in key international markets. The patented connector is part of IceCure's cryogenic technology platform. The patent grant follows a recent regulatory milestone in China, where in September 2026, IceCure received approval from China's National Medical Products Administration to market its ProSense® system and associated cryoprobes in China. IceCure's intellectual property portfolio now contains 42 patents across the United States, Europe, Great Britain, China, and Japan. The portfolio covers the company's technological platform and proprietary technologies, including innovations intended for incorporation into current and future products. IceCure continues to protect and expand its intellectual property portfolio across international markets to support its long-term technology strategy and protect its proprietary innovations. The company's flagship ProSense® system is marketed and sold worldwide for indications cleared and approved to date, including in the U.S., Europe, and Asia. ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients not eligible for surgery. Meir Peleg is the Chief Financial Officer of IceCure Medical Ltd.

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

(NASDAQ:ICCM) IceCure Medical Ltd. announced the successful completion of the first patient treatment in its post-marketing ChoICE Study evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer. The first patient was treated at West Cancer Center & Research Institute in Germantown, Tennessee by Dr. Richard E. Fine, MD, FACS, who is a board-certified breast oncology surgeon and Director of the Breast Surgical Oncology Fellowship Program. The ChoICE Study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites. The study aims to generate real-world data on ProSense® in its U.S. Food and Drug Administration (FDA) cleared indication. Participating sites are expected to serve both as study centers and as active commercial sites, enabling them to offer ProSense® cryoablation to eligible patients who are not participating in the ChoICE Study. ProSense® cryoablation is the first and only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. Eyal Shamir, Chief Executive Officer of IceCure Medical, stated that initiating treatment in the ChoICE Study is a key step in executing the company’s U.S. post-market strategy for ProSense®. Dr. Fine commented that treating the first patient marks an exciting milestone for the ChoICE Study, which is expected to generate additional clinical data supporting cryoablation and help pave the way for broader clinical adoption among appropriately selected breast cancer patients. IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors, with primary focus areas including breast, kidney, bone, and lung cancer. The ProSense® system is marketed and sold worldwide for the indications cleared and approved to date, including in the U.S., Europe, and Asia.

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

(NASDAQ:ICCM) IceCure Medical Ltd. announced that its ProSense® breast cancer cryoablation system was featured in multiple scientific presentations, research posters, and physician workshops at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands. The event included the presentation of 12-month clinical data showing an objective response rate of 97.5% among 40 patients treated with cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone. ProSense® was highlighted in two key scientific sessions, reflecting growing clinical interest in breast cancer cryoablation in Europe. Dr. Lucía Graña-López (Lugo, Spain) presented on the clinical potential of cryoablation in the session "From Target to Treatment: Breast Interventions." Dr. Francesca Pugliese (Florence, Italy) shared findings on local tumor control in elderly breast cancer patients ineligible for surgery, comparing cryoablation alone and in combination with hormonal therapy. IceCure Medical hosted two clinical workshops led by Dr. Lucía Graña-López and Dr. Federica Di Naro (Florence, Italy), titled "From Freeze to Future: Cryoablation as a New Frontier in De-Escalated Breast Cancer Care" and "Reading the Freeze: Practical Imaging Interpretation After Breast Cancer Cryoablation," each attracting nearly 70 participants. Two scientific posters by ProSense® users were presented: one by Dr. Georgiana-Cristiana Camen (Romania) on single-center efficacy and safety outcomes for breast lesion cryoablation, and another by Dr. Francesca Pugliese on the predictive value of negative contrast enhancement mammography after breast cryoablation. EUSOBI is a leading European organization for breast imaging and education, and its annual meeting serves as a platform for sharing clinical knowledge and research advances. Eyal Shamir, Chief Executive Officer of IceCure Medical, stated that the company was thrilled by the enthusiasm and engagement ProSense® generated at EUSOBI, noting the strong response to live demonstrations, scientific sessions, workshops, and the presentation of encouraging 12-month clinical results. The ProSense® system is marketed and sold worldwide for approved indications, including in the United States, Europe, and Asia. ProSense® cryoablation is the first and only medical device cleared by the FDA for local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including those not eligible for surgery.

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

(NASDAQ: ICCM) IceCure Medical Ltd. announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the Company's post-marketing study (ChoICE Study) for ProSense® cryoablation in the local treatment of low-risk breast cancer. ProSense® is the first and only medical device to be granted U.S. Food and Drug Administration (FDA) marketing authorization for the local treatment of low-risk breast cancer with endocrine therapy in women aged 70 and above. The successful results from the Company's ICE3 clinical trial demonstrated that ProSense® cryoablation followed by endocrine therapy achieved a 3.1% rate of local recurrence in women with early-stage, low-risk breast cancer. 99.1% of patients and 97% of physicians that responded to a survey reported high rates of satisfaction with the cosmetic outcomes. Under the approved study design, 30 participating sites will serve both as ChoICE Study centers and as active commercial sites, enabling them to enroll a total of 400 patients while also offering ProSense® cryoablation to appropriate patients who are not participating in the ChoICE Study. The site will be led by Dr. Richard Gilmore, MD, MBA, DipABLM, a breast surgical oncologist at the Margaret West Comprehensive Breast Center, part of West Cancer Center & Research Institute. IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

(NASDAQ:ICCM) IceCure Medical Ltd. announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE" for ProSense® cryoablation in the treatment of low-risk breast cancer, following FDA marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across 30 U.S. sites, gathering real-world data to support further clinical adoption and broader access for eligible patients. ProSense® is cleared by the U.S. Food and Drug Administration for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. Under the approved study design, 30 participating sites will serve both as ChoICE Study sites and as active commercial sites, enabling them to enroll and treat a total of 400 patients while also offering ProSense® cryoablation to appropriate patients who are not participating in the ChoICE Study. IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors, with primary focus areas being breast, kidney, bone, and lung cancer. The company projects that the ChoICE Study and the resulting data will support clinical and commercial adoption of ProSense® and broader patient access. The West Cancer Center & Research Institute has served the Mid-South for 47 years and continues as the leader in adult cancer care.

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

(NASDAQ:ICCM) IceCure Medical Ltd. announced the expansion of its United States sales and marketing teams. The company reported a 70% growth in its active U.S. commercial install base of ProSense® for breast cancer cryoablation, as previously announced on June 17, 2026. This growth was driven by the U.S. Food and Drug Administration ("FDA") marketing authorization in October 2025, supportive clinical guidelines, and growing physician demand. IceCure has added new ProSense® systems at clinics and hospitals across the U.S., with procedures now being performed in major metropolitan areas including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, and Memphis. The company develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors, with primary focus areas being breast, kidney, bone, and lung cancer. The company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia. The company projects continued strong demand for ProSense® in the U.S., continued expansion of its U.S. commercial team, clinical support and geographic footprint, and plans to raise awareness of its cryoablation treatment and make ProSense® available to patients in additional territories and regions.

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

(NASDAQ: ICCM) IceCure Medical Ltd. announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents), Series D Warrants to purchase up to 1,833,334 ordinary shares, and Series E Warrants to purchase up to 1,833,334 ordinary shares at a combined purchase price of $3.00 per share and accompanying Warrants in a private placement. The gross proceeds from the offering are expected to be approximately $5.5 million, before deducting placement agent commissions and other estimated offering expenses. The Warrants will have an exercise price of $3.00 per share, with the Series D Warrants expiring five years following the date of issuance and the Series E Warrants expiring one year following the date of issuance. The closing of the offering is expected to occur on or about June 18, 2026, subject to the satisfaction of customary closing conditions. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the ordinary shares and ordinary shares underlying warrants sold in the offering. Upon obtaining shareholder approval, the exercise price of the March 2026 Warrants to purchase up to an aggregate of 266,666 ordinary shares will be reduced from $16.50 per share to $3.00 per share. The Series B Warrants will expire in June 2031 and the Series C Warrants will expire in June 2027.